...and CEO Sommadossi, who helped found two antiviral companies that were acquired in multibillion-dollar deals: Idenix Pharmaceuticals Inc....

...CEO Jean-Pierre Sommadossi, who helped found two antiviral companies that were acquired in multibillion-dollar deals: Idenix Pharmaceuticals Inc....

...Led by Idenix, Pharmasset co-founder, Atea is fresh off $215M round led by Bain By Jeff...
...veteran biotech entrepreneur who helped found two antiviral companies that were acquired in multibillion-dollar deals: Idenix Pharmaceuticals Inc....

...any damage until there’s a vaccine,” Sommadossi said. Sommadossi helped found two prior antiviral companies: Idenix Pharmaceuticals Inc....

...she was also interim CFO at Neon Therapeutics Inc. (NASDAQ:NTGN), and was previously CFO of Idenix...

...Inc. (NASDAQ:GILD) following its $11 billion acquisition in 2011. Mayers was EVP and CMO of Idenix Pharmaceuticals Inc....
...which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014. The pharma dropped Idenix's...

...Inc. (NASDAQ:GILD) following its $11 billion acquisition in 2011. Mayers was EVP and CMO of Idenix Pharmaceuticals Inc....
...which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014. The pharma dropped Idenix's...

...gained uprifosbuvir (MK-3682), a component of MK-3682B and MK-3682C, through its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....

...gained uprifosbuvir (MK-3682), a component of MK-3682B and MK-3682C, through its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....

...gained uprifosbuvir (MK-3682), a component of MK-3682B and MK-3682C, through its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....